Literature DB >> 20670292

Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains.

Y Keynan1, C M Card, B T Ball, Y Li, F A Plummer, K R Fowke.   

Abstract

Influenza vaccine provides protection against infection with matched strains, and this protection correlates with serum antibody titres. In addition to antibodies, influenza-specific CD8+ T-lymphocyte responses are important in decreasing disease severity and facilitating viral clearance. Because this response is directed at internal, relatively conserved antigens, it affords some cross-protection within a given subtype of influenza virus. With the possibility of a broader A(H1N1) Mexico outbreak in the fall of 2009, it appeared worthwhile studying the degree of cellular immune response-mediated cross-reactivity among influenza virus isolates. The composition of the 2006-2007 influenza vaccine included the A/New Caledonia/20/1999 strain (comprising a virus that has been circulating, and was included in vaccine preparations, for 6-7 years) and two strains not previously included (Wisconsin and Malaysia). This combination afforded us the opportunity to determine the degree of cross-reactive cellular immunity after exposure to new viral strains. We analysed the antibody responses and the phenotype and function of the T cell response to vaccine components. The results obtained show that antibody responses to A/New-Caledonia were already high and vaccination did not increase antibody or cytotoxic T lymphocyte responses. These data suggest that repeated exposure to the same influenza stain results in limited boosting of humoral and cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670292     DOI: 10.1111/j.1469-0691.2010.03142.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.

Authors:  Hugues de Lavallade; Paula Garland; Takuya Sekine; Katja Hoschler; David Marin; Kate Stringaris; Eva Loucaides; Katherine Howe; Richard Szydlo; Ed Kanfer; Donald Macdonald; Peter Kelleher; Nichola Cooper; Ahmad Khoder; Ian H Gabriel; Dragana Milojkovic; Jiri Pavlu; John M Goldman; Jane F Apperley; Katayoun Rezvani
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.

Authors:  Chiara Agrati; Cristiana Gioia; Concetta Castilletti; Daniele Lapa; Giulia Berno; Vincenzo Puro; Fabrizio Carletti; Eleonora Cimini; Carla Nisii; Flora Castellino; Federico Martini; Maria R Capobianchi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

3.  Seroprevalence of pandemic (H1N1) 2009 in pregnant women in China: an observational study.

Authors:  Xiang Huo; Xian Qi; Fenyang Tang; Rongqiang Zu; Liang Li; Bin Wu; Yuanfang Qin; Hong Ji; Jianguang Fu; Shenjiao Wang; Hua Tian; Zhibin Hu; Haitao Yang; Minghao Zhou; Hua Wang; Fengcai Zhu
Journal:  PLoS One       Date:  2011-03-18       Impact factor: 3.240

4.  Inter-individual variation in health and disease associated with pulmonary infectious agents.

Authors:  Kirsten C Verhein; Heather L Vellers; Steven R Kleeberger
Journal:  Mamm Genome       Date:  2018-02       Impact factor: 2.957

5.  Efficacy of Heterologous Prime-Boost Vaccination with H3N2 Influenza Viruses in Pre-Immune Individuals: Studies in the Pig Model.

Authors:  Sharon Chepkwony; Anna Parys; Elien Vandoorn; Koen Chiers; Kristien Van Reeth
Journal:  Viruses       Date:  2020-09-01       Impact factor: 5.048

6.  T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity.

Authors:  Jose L Casado; Johannes Haemmerle; Pilar Vizcarra; Mario Rodriguez-Dominguez; Tamara Velasco; Hector Velasco; Elena Centenera; Beatriz Romero-Hernandez; Marina Fernandez-Escribano; Alejandro Vallejo
Journal:  Clin Transl Immunology       Date:  2021-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.